Fixed Duration Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Maintenance Leads to High Rates of Sustained MRD Negativity in Patients with High-Risk Smoldering Multiple Myeloma: Long Term Follow up of an Investigator Initiated Phase 2 Trial
Year: 2023
Type: conference-abstract
Source: Blood
Authors: Elizabeth Hill, Joseph L. Roswarski, Amrit Bhaskarla, Alexander Dew, Candis Morrison, Michael Emanuel, Ani Petrosyan, Hao-Wei Wang, Constance M. Yuan, Liza Lindenberg, Esther Mena, Baris Turkbey, Nisha Patel, Irina Maric, Alina Dulau-Florea, Katherine Calvo, Raul C. Braylan, Maryalice Stetler-Stevenson, Seth M. Steinberg, William Figg, Ryan M. Young, Ola Landgren, Mark Roschewski, Dickran Kazandjian
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4389230441